论文信息 - Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. - 字舞流文

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.

Amalio Telenti | Vincent Mooser | Thierry Buclin | Pascal Nicod | Catia Marzolini | A. Telenti | V. Mooser | T. Buclin | C. Marzolini | J. Chave | P. Nicod | B. Waeber | F. Feihl | A. Pannatier | Bernard Waeber | Jean-Philippe Chave | R. Darioli | André Pannatier | Roger Darioli | François Feihl | Nicole Doser | Sandrine Kübli | N. Doser | Sandrine Kübli

[1] A. Telenti,et al. Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy , 2001, AIDS.

[2] B Waeber,et al. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. , 2000, Journal of cardiovascular pharmacology.

[3] A. Telenti,et al. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[4] S M Marcovina,et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[5] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[6] A. Gotto,et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.